Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia.
about
The potential of venetoclax (ABT-199) in chronic lymphocytic leukemiaPI3K and cancer: lessons, challenges and opportunitiesModulating cell-to-cell variability and sensitivity to death ligands by co-drugging.Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibitionMCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosisIdelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.Do mantle cell lymphomas have an 'Achilles heel'?BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy responseImpact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia.Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia.Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells.BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis.Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agentsPhosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia.Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinibBiology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.Specific inhibition of PI3K p110δ inhibits CSF-1-induced macrophage spreading and invasive capacityImpact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice.Mitochondria: gatekeepers of response to chemotherapyHow to unleash mitochondrial apoptotic blockades to kill cancers?Multiple components of the spliceosome regulate Mcl1 activity in neuroblastoma.The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells.The current status and future impact of targeted therapies in non-Hodgkin lymphoma.Achieving cancer cell death with PI3K/mTOR-targeted therapiesIbrutinib in chronic lymphocytic leukemia and B cell malignancies.Diffuse large B-cell lymphoma-treatment approaches in the molecular era.Apoptosis regulation at the mitochondrial outer membrane.Harnessing system models of cell death signalling for cytotoxic chemotherapy: towards personalised medicine approaches?Ibrutinib in B-cell Lymphomas.How we manage follicular lymphoma.Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin's lymphoma.Venetoclax for the treatment of patients with chronic lymphocytic leukemia.Senescent stromal cell-induced divergence and therapeutic resistance in T cell acute lymphoblastic leukemia/lymphomaMitochondria-Judges and Executioners of Cell Death Sentences.To Prime, or Not to Prime: That Is the Question.Targeting neddylation effectively antagonizes nuclear factor-κB in chronic lymphocytic leukemia B-cells.The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine.
P2860
Q28075504-18F7667D-2C71-4730-ADB5-7B573D869388Q30080017-6C80943F-91F8-420C-8DCB-EDE8D1CBD08AQ30544925-D4D0EAE3-BAE8-420E-940A-6B056F39332EQ33407258-BCD5C7C8-2DFA-4E0D-9D4D-E403900E1FD1Q33419789-40ECC3C0-7DBB-49AC-9BE4-1D3A71B75B51Q33785941-C8654CF9-CCC5-47FB-BBFB-615EA6C67152Q34009003-D932EB8F-2D97-414C-8423-4007621F6D99Q34090009-43025B5E-EBA1-40F2-B567-894E4B53F754Q34182014-C6A960D0-E0F3-49AE-958F-BB3269F030B1Q34231324-A0D2F0C2-D662-476E-B526-64242F0F10DFQ34231446-759AC692-1D68-4BDC-AECE-875D92D20376Q35836864-87619FF1-01B5-4D85-AD0A-C1E53EAFEAF6Q35852684-F5AF2868-3B37-4C1B-A6B3-6F7393ED9571Q36284637-A94157D4-3128-4392-8BF8-F35E85C7CEABQ36293814-932B72E4-F4F1-4E96-901C-60243B585D02Q36737287-82882D7E-A17F-44F0-AAFC-25272CD5A592Q36782516-5FAB1739-C4D1-4681-9D7C-0FEE3DC00D34Q36862781-2515632E-298F-4455-B5FB-6BFDB0BBF9FFQ37035832-FECEC7E1-C984-4319-989B-41D4BAFD9D10Q37170570-07592542-0460-415D-AF44-78CDB58CEE3EQ37330840-99E5B9E0-D667-4535-988B-5D1FE57D2E92Q37347485-E04F4420-1A26-432D-B17B-23F6BFF0CD09Q37587294-6C9C852A-E874-4E81-96CB-1C51794A5B9FQ37620684-D6FB9070-1636-436B-9EF9-7708C6D9A81FQ37649732-E02A24EB-F7B7-4094-8D14-CFE8880A61C4Q38095123-099E6B57-0758-407D-A5C1-B760269083F6Q38095573-54F7C28E-395D-451F-AF7E-393E6A69B74AQ38105129-52EC3ACA-0F19-4F15-8A7D-00C9EC5589FAQ38161760-9298ABFB-31BD-4907-AC24-8B56CE44CF68Q38181031-756864F4-1C15-4E79-9EBC-EA854C5C9191Q38183302-F32323F7-2934-4ECE-BBDB-AEF9D0229089Q38183759-CF090FA0-B3EF-41EE-B3DE-F93F3D89BB5CQ38191811-F5979809-9E55-4C97-97B3-568DF3928306Q38338496-6CF6FA18-9CB6-4455-9414-2FA5F4259B36Q38685358-9A8EC04C-BE16-4F6A-847A-D8053E4D915DQ38731737-3B956F1E-B1E2-4078-93BE-98E219B0B19AQ38760561-F43BED20-1501-41EA-A0B5-46CA56218A37Q38798849-408EB9C8-716E-43BF-89BD-4F1878D45EDDQ38862584-365A882B-34B7-45E7-BCCF-4BC7C65A937AQ38895643-94F3CA83-61D9-4A56-911D-255613DEAC83
P2860
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Decreased mitochondrial apopto ...... chronic lymphocytic leukemia.
@ast
Decreased mitochondrial apopto ...... chronic lymphocytic leukemia.
@en
type
label
Decreased mitochondrial apopto ...... chronic lymphocytic leukemia.
@ast
Decreased mitochondrial apopto ...... chronic lymphocytic leukemia.
@en
prefLabel
Decreased mitochondrial apopto ...... chronic lymphocytic leukemia.
@ast
Decreased mitochondrial apopto ...... chronic lymphocytic leukemia.
@en
P2093
P2860
P921
P1433
P1476
Decreased mitochondrial apopto ...... chronic lymphocytic leukemia.
@en
P2093
Adrian Wiestner
Anthony Letai
Brian J Lannutti
Catherine J Wu
Jennifer R Brown
Matthew S Davids
Wyndham H Wilson
P2860
P304
P356
10.1182/BLOOD-2012-02-414060
P407
P577
2012-09-05T00:00:00Z